Provided By GlobeNewswire
Last update: Oct 10, 2024
ROCKVILLE, Md., Oct. 10, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and innovative bioprocessing applications, today announced the appointment of Ali Soleymannezhad as Chief Commercial Officer, effective as of September 11, 2024.
NASDAQ:MXCT (4/25/2025, 11:53:54 AM)
2.84
0 (0%)
Find more stocks in the Stock Screener